NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

肥胖:消化管荷爾蒙受體受到商業性的關注

Obesity: Gut Hormone Receptors Retain Commercial Prominence

出版商 GlobalData 商品編碼 865065
出版日期 內容資訊 英文 46 Pages
訂單完成後即時交付
價格
肥胖:消化管荷爾蒙受體受到商業性的關注 Obesity: Gut Hormone Receptors Retain Commercial Prominence
出版日期: 2019年05月31日內容資訊: 英文 46 Pages
簡介

本報告提供全球肥胖市場相關調查,疾病概要,開發平台分析、比較與各開發階段、分子類型、分子標的的分層,及First-in-Class標的治療潛在性的評估等。

第1章 目錄

第2章 肥胖:摘要整理

第3章 簡介

第4章 疾病概要

  • 病因與病理學
  • 分類或分期系統
  • 肥胖在於持續的革新
  • 肥胖的流行病學
  • 上市藥概要

第5章 開發中產品革新的評估

  • 概要
  • 開發平台:各開發階段、分子類型
  • 開發平台:各分子標的
  • 肥胖市場與開發平台間的計劃比較分佈:治療標的各系列
  • First-in-Class和非First-in-Class開發平台計劃比較分佈:各分子目標類別
  • 對開發平台的First-in-Class分子標的之First-in-Class計劃比率

第6章 First-in-Class分子標的評估

  • 概要
  • 以BMPR2為標的開發平台計劃
  • 以BMPR1A為標的開發平台計劃
  • 以FADS1為標的開發平台計劃
  • 以BMPR1B為標的開發平台計劃
  • 以SLC27A2為標的開發平台計劃
  • 以SREBF1為標的開發平台計劃
  • 以ADIPOQ為標的開發平台計劃
  • 以C3AR1為標的開發平台計劃
  • 以ACACB為標的開發平台計劃

第7章 主要企業、契約

第8章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC496FP

Obesity is a chronic and potentially fatal disease. The most prevalent metabolic disorder affecting people today, obesity requires multidisciplinary continuing treatment. Despite the market's clinical and regulatory challenges, the obesity pipeline is robust and contains a high level of diversity in both molecule types and molecular targets, which is in line with its multifactorial etiology. The primary concern within the market is the need for medications that adequately address the unmet clinical needs in the overweight and obese population, namely efficacious and safe therapies. This report assesses first-in-class innovation across the obesity pipeline.

Scope

  • The obesity pipeline is robust and contains a high level of diversity in both molecule types and molecular targets. Which drug classes are used to treat this disease? How do the drug classes in the market compare with those in the pipeline?
  • There are 267 pipeline programs in active development for obesity, respectively. What proportion of these products are first-in-class? How does first-in-class innovation vary by indication, development stage and molecular target class?
  • Which molecular target classes are prominently represented in the first-in-class obesity pipeline? Which first-in-class targets have been identified as most promising for obesity, and is there any overlap?
  • Which companies are the key players within the obesity market? Who has been involved in the most licensing and co-development deals for obesity products? Which first-in-class products have prior deal involvement?

Reasons to buy

  • Understand the current disease landscape with an overview of etiology, pathophysiology, disease classification and staging systems, epidemiology, and treatment options for obesity.
  • Visualize the composition of the obesity markets in terms of dominant molecule types and molecular targets. This knowledge allows a competitive understanding of gaps in the current market.
  • Analyze and compare the obesity pipeline and stratify by stage of development, molecule type, and molecular target.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products for each indication have been assessed and ranked according to clinical potential. Promising first-in-class targets have been reviewed in greater detail.
  • Recognize commercial opportunities by identifying first-in-class obesity pipeline products that have not yet been involved in licensing or co-development deals, and by analyzing company strategies in prior deals through case studies of key deals for obesity first-in-class products.

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Obesity: Executive Summary

  • 2.1 The Need for Further Novel Therapies
  • 2.2 Pipeline Shows Increasing Innovation
  • 2.3 Deals Landscape presents Investment Opportunities

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
  • 4.2 Classification or Staging Systems
  • 4.3 Sustained Innovation in Obesity
  • 4.4 Epidemiology for Obesity
  • 4.5 Overview for Marketed Products

5 Assessment of Pipeline Product Innovation

  • 5.1 Overview
  • 5.2 Pipeline by Stage of Development and Molecule Type
  • 5.3 Pipeline by Molecular Target
  • 5.4 Comparative Distribution of Programs Between Obesity Market and Pipeline by Therapeutic Target Family
  • 5.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class
    • 5.5.1 Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Programs
  • 5.6 Ratio of First-in-Class Products to First-in-Class Molecular Target within the Pipeline

6 First-in-Class Molecular Target Evaluation

  • 6.1 Overview
  • 6.2 Pipeline Programs Targeting BMPR2
  • 6.3 Pipeline Programs Targeting BMPR1A
  • 6.4 Pipeline Programs Targeting FADS1
  • 6.5 Pipeline Programs Targeting BMPR1B
  • 6.6 Pipeline Programs Targeting SLC27A2
  • 6.7 Pipeline Programs Targeting SREBF1
  • 6.8 Pipeline Programs Targeting ADIPOQ
  • 6.9 Pipeline Programs Targeting C3AR1
  • 6.10 Pipeline Programs Targeting ACACB

7 Key Players and Deals

  • 7.1 Overview
    • 7.1.1 Zafgen Licensing Deal with Children's Medical Center Corporation
    • 7.1.2 Diasome Pharmaceuticals Signs Licensing Deal with SDG
    • 7.1.3 Evotec Co-development Deal with Eternygen

8 Appendix

  • 8.1 Bibliography
  • 8.2 Abbreviations
  • 8.3 Methodology
    • 8.3.1 Market Analysis
    • 8.3.2 Overall Pipeline Analysis
    • 8.3.3 First-in-Class Pipeline Analysis
    • 8.3.4 First-in-Class Matrix Assessment
    • 8.3.5 First-in-Class Molecular Target Evaluation
    • 8.3.6 Key Players and Deals
  • 8.4 About the Authors
    • 8.4.1 Analyst
    • 8.4.2 Therapy Area Director
    • 8.4.3 Global Director of Therapy Analysis and Epidemiology
    • 8.4.4 Global Head and EVP of Healthcare Operations and Strategy
  • 8.5 About GlobalData
  • 8.6 Contact Us
  • 8.7 Disclaimer

List of Tables

  • Table 1: Nutritional status
  • Table 2: Obesity Total Prevalent Cases (Millions), 2012-2022

List of Figures

  • Figure 1: Obesity, Global Market by Molecular Target and Molecule Type, 2019
  • Figure 2: Obesity, Global, Pipeline by Stage of Development and Molecule Type, 2019
  • Figure 3: Obesity Global Pipeline, by Molecular Target and Stage of Development, 2019
  • Figure 4: Obesity, Global, Distribution of Pipeline and Marketed Products by Molecular Target Class, 2019
  • Figure 5: Obesity, Global, Distribution of Pipeline Products by First-in-Class Status and Molecular Target Class, 2019
  • Figure 6: Obesity, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target Class, 2019
  • Figure 7: Obesity, Global, Ratio of First-in-Class and Non-First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2019